explore -WSS

explore

author：Wikipedia 2025-10-02 02:16:23 - browse：15

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Senate panel eyes new effort on drug shortages

entertainment

focus

WSS

Senators tussle over abortion against the backdrop of a presidential campaign

The future of health care in the House

Sana to lay off nearly a third of staff, de

Elevance PBM president out as customers face prescription chaos

Analysis of telehealth claims data suggest service duplication

Sutter Health’s antitrust win overturned by appeals court

hotspot

explore

leisure time

In age of alternative facts, a scholarly course on calling out crap

Eli Lilly’s Zepbound improved liver scarring in mid

Guidelines to prevent youth baseball injuries need more muscle

BD to buy Edwards patient monitoring unit for $4.2 billion

Psychedelics group wrestles with new pharma identity

FDA authorizes Novavax’s updated Covid

Jerome Adams on the need for new antivirals for Covid

Chan Zuckerberg Biohub Chicago to focus on inflammation

United colonoscopy coverage change 'may cost lives,' doctors say

Finland to offer bird flu vaccine to select groups of people, a possible global first

leisure time

Finland to offer bird flu vaccine to select groups of people, a possible global first

When women are denied an abortion, their children fare worse than peers

STAT wants to know your pick for a great summer read or listen

The most pressing bird flu mysteries scientists want answered

Stroke deaths set to near 10 million globally by 2050

Eli Lilly’s Zepbound improved liver scarring in mid

entertainment

focus

focus

hotspot